{"doi":"10.3389/fmed.2022.961071","title":"Prognostic value of proadrenomedullin in patients with COVID-19 pneumonia","abstract":"<jats:sec><jats:title>Objective</jats:title><jats:p>The aim of the study was to assess the role of mid-regional proadrenomedullin (MR-proADM) in comparison with routine laboratory tests in patients with COVID-19.</jats:p></jats:sec><jats:sec><jats:title>Materials and methods</jats:title><jats:p>140 hospitalized patients aged 18 and older with COVID-19 pneumonia were included in prospective single-center study. Routine analyses were performed, and MR-proADM level was measured within the first and the third hospital days using Human MR pro-ADM (Mid-regional pro-adrenomedullin) ELISA Kit with a sensitivity of 0.469 pmol/L (immunofluorescence assay). National Early Warning Score (NEWS) was used for primary assessment of the disease severity. According to disease outcome the patients were divided into two groups: discharged patients (<jats:italic>n</jats:italic> = 110, 78.6%) and deceased patients (<jats:italic>n</jats:italic> = 30, 21.4%). Results: The groups had no statistically significant difference in sex, comorbidity, body temperature, oxygen saturation level, heart rate, respiratory rate, and C-reactive protein (CRP) level and procalcitonin (PCT). The deceased patients had statistically significant difference in age (median, 76 years; interquartile range, 73.2–78.2 vs. median, 66 years; interquartile range, 62–67; <jats:italic>p</jats:italic> &amp;lt; 0.0001), NEWS value (median, 5; interquartile range, 3–8 vs. median, 2; interquartile range, 0–6; <jats:italic>p</jats:italic> &amp;lt;0.05), hospitalization period (median, 17; interquartile range, 7–35 vs. median, 6; interquartile range, 3–14), quantitative CT extent of lung damage &amp;gt; 50% [<jats:italic>n</jats:italic> = 26 (86.7%) vs. <jats:italic>n</jats:italic> = 9 (8.2%) <jats:italic>p</jats:italic> &amp;lt; 0.0001], level of leukocytes (median, 11.4 ×109/L; interquartile range, 6.2–15.5 vs. median, 5.3 ×109/L; interquartile range, 4.7–6.4; <jats:italic>p</jats:italic> = 0.003), level of neutrophils (median, 80.9%; interquartile range, 73.6–88.6 vs. median, 72.6%; interquartile range, 68.7–76.9; <jats:italic>p</jats:italic> = 0.027), level of MR-proADM at the first hospital day (median, 828.6 pmol/L; interquartile range, 586.4–1,184.6 vs. median, 492.6 pmol/L; interquartile range, 352.9–712.2; <jats:italic>p</jats:italic> = 0.02), and level of MR-proADM at the third hospital day (median, 1,855.2 pmol/L; interquartile range, 1,078.4–2,596.5 vs. median, 270.7 pmol/L; interquartile range, 155.06–427.1).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Mid-regional proadrenomedullin has a higher prognostic value in patients with COVID-19 in comparison with routine inflammatory markers (leukocyte and neutrophils levels, CRP, and PCT) and NEWS.</jats:p></jats:sec>","journal":"Frontiers in Medicine","year":2022,"id":18729,"datarank":0.2777949682011074,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.06985081403312375,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.06985081403312375,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":3,"citers_with_citation_signal":2,"citers_with_endowment":2,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":129157,"name":"Vladimir N. Drozdov","orcid":null,"position":1,"is_corresponding":false},{"id":129158,"name":"Evgenia V. Shikh","orcid":null,"position":2,"is_corresponding":false},{"id":129159,"name":"George G. Melkonyan","orcid":null,"position":3,"is_corresponding":false},{"id":129161,"name":"Zhanna M. Sizova","orcid":null,"position":4,"is_corresponding":false},{"id":129163,"name":"Valeria L. Zakharova","orcid":null,"position":5,"is_corresponding":false},{"id":129165,"name":"Natalia N. Shindryaeva","orcid":null,"position":6,"is_corresponding":false},{"id":129166,"name":"Natalia I. Lapidus","orcid":null,"position":7,"is_corresponding":false},{"id":129156,"name":"Aleksandr A. Astapovskii","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36072940","pmcid":"PMC9441885","openalex_id":"https://openalex.org/W4292573045","authors":[],"funders":[],"total_grants":0,"fwci":0.4533,"citation_percentile":0.64316388,"influential_citations":1,"citation_trend":[{"year":2023,"count":2},{"year":2025,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.frontiersin.org/articles/10.3389/fmed.2022.961071/pdf","host_type":"journal"},{"url":"https://www.frontiersin.org/articles/10.3389/fmed.2022.961071/pdf","host_type":"GOLD"},{"url":"https://www.frontiersin.org/articles/10.3389/fmed.2022.961071/pdf","host_type":"publisher"},{"url":"https://www.frontiersin.org/articles/10.3389/fmed.2022.961071/full","host_type":"publisher"},{"url":"https://doi.org/10.3389/fmed.2022.961071","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36072940","host_type":"repository"},{"url":"https://doaj.org/article/5f2d9dff96894422bf9c4fc03ec6bb20","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9441885","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9441885","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9441885?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Respiratory Support and Mechanisms","Neuropeptides and Animal Physiology","Pharmacological Receptor Mechanisms and Effects","Medicine"],"mesh_terms":[],"keywords":["Interquartile range","Medicine","Internal medicine","Prospective cohort study","Procalcitonin","Pneumonia","Coronavirus disease 2019 (COVID-19)","ARDS","Gastroenterology","Lung","Disease","Sepsis","Biomarkers","Proadrenomedullin","Coronavirus","Nephrology","Covid-19"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-03T23:18:25.730718Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}